Drugs in Chronic Kidney Disease: Implications for Pharmacists

Tags: Online learning, Medication therapy management, Chronic conditions


Note: this course is included in the OPA Clinical Bundle.

The term chronic kidney disease (CKD) describes the different stages of chronic renal failure, including end-stage renal failure. Assessing and managing CKD in patients can be difficult due to comorbid conditions, numerous medications, and altered pharmacokinetics. This online module will help pharmacists understand the classification system for kidney dysfunction and the implications of drug dosing. It will also discuss medications to avoid in patients with CKD and summarize common drugs that require dose adjustments.

This presentation received great uptake at OPA’s Conference 2016.

Learning Objectives

Upon completion of this program, participants will be able to

  • Discuss the classification system for kidney dysfunction.
  • Review changes in the kidneys of the elderly.
  • Describe ways to prevent kidney disease the development.
  • Summarize common drugs requiring dose adjustments.
  • Summarize drugs that can cause kidney injury.


Number of Continuing Education Units

Accreditation #

Expiry Date
February 7, 2020

Learning Format

  • Online, didactic learning module (1 hr)
  • Interactive questions
  • Learner assessment

Multiple-choice assessment

Program Completion

To receive a letter of completion for this program, participants must complete the following requirements before February 6, 2020:

  1. Complete the program’s online modules. Instructions will be emailed to you separately after registration.
  2. Complete the multiple-choice exam, achieving a score of 70 per cent or higher within a maximum two attempts.
  3. Complete a program evaluation.
Note: access to this program is provided until Feb 6, 2020.

Prerequisites and Target Audience

The Drugs in Chronic Kidney Disease: Implications for Pharmacists online module was designed for pharmacists wishing to gain a better understanding of drug management in patients with CKD.

Subject Matter Experts 

  • Marisa Battistella, RPh, ACPR (BScPhm, PharmD)
  • Louise Moist, MD (MSc)
  • Lisa Zhu, RPh, ACPR (BScPhm, PharmD)

Last updated: February 7, 2019

Inquiries: Please contact OPA’s professional development team by phone at 416-441-0788, option 3 (toll-free in Ontario at 1-877-341-0788, option 3), or by email at education@opatoday.com.

Cancellation policy: Cancellation requests must be submitted in writing to education@opatoday.com no later than five days after access to the program has been emailed to you. An administration and processing fee may apply. Cancellations will not be permitted once log-in to access the program material has been initiated. Program registration fees will not be refunded after the cancellation deadline.

Protecting your privacy: Your privacy is important to us. Some information you provide in program registration forms and exercises may be considered personal information. OPA collects, uses, and shares the information contained in program registration forms and exercises to process your registration; issue certificates of completion; award continuing education credits; and deliver OPA services, programs, and publications to you.

Learners’ code of conduct: By registering for an OPA education program, you agree to follow OPA’s Learners’ Code of Conduct. For further details, click here

Event Date: Recurring | City: Online | Venue: Online

Pricing and Registration
Member Rate
Chronic Kidney Diease   $15.00 Add to Cart 
Non-Member Rate
Chronic Kidney Diease   $30.00 Add to Cart 
Back to top